RxDoctor Payments DataLook up a doctor →

Maninder Bedi, MD

Cardiovascular Disease · Weirton, WVNPI 1003851213

Payments from drug & device makers

$332,721in general payments, 2019–2025

Across 712 payments — averaging $467.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$148K
  • Boston Scientific$127K
  • Impulse Dynamics (USA) Inc.$14K
  • Baylis Medical Company Inc$12K
  • Abbott$10K
  • Biosense Webster, Inc.$10K
  • plus $13K from 32 others

What the payments were for

  • Consulting fees$22,33210%
  • Speaking & faculty fees$142,70062%
  • Travel & lodging$40,95218%
  • Food & beverage$24,23011%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$332,721 in reported general payments places this provider in the 95th percentile of 100 cardiovascular disease providers in West Virginia.

See all cardiovascular disease providers in West Virginia

Medicare billing

Part B allowed, 2024
$616,932
Medicare patients
2,098
Services billed
11,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,350$1,127,639
XareltoRivaroxaban376$332,525
Dofetilide598$115,643
Propafenone Hcl ErPropafenone Hcl389$65,758
EntrestoSacubitril/Valsartan40$41,280
MultaqDronedarone Hcl33$32,716
Flecainide Acetate544$19,071
Amiodarone Hcl1,094$17,158
Mexiletine Hcl142$11,688
Metoprolol Succinate1,019$10,202
Diltiazem 24hr Er (Cd)Diltiazem Hcl246$6,265
Propafenone Hcl110$4,999
Verapamil SrVerapamil Hcl44$4,215
SotalolSotalol Hcl208$3,878
Midodrine Hcl55$2,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$1,127,6391,350 claims
Johnson & JohnsonXarelto$127$332,525376 claims
NovartisEntresto$38$41,28040 claims
Sanofi-aventis U.S. LLCMultaq$2,660$32,71633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 100 cardiovascular disease providers in West Virginia.

Other cardiovascular disease in Weirton

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →